Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Jun 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Bendamustine (Primary) ; Gemcitabine (Primary) ; Lenalidomide (Primary) ; Oxaliplatin (Primary) ; Rituximab (Primary)
Indications Diffuse large B cell lymphoma
Focus Therapeutic Use
Acronyms Relyage

13 Jun 2024 This trial has been discontinued in France, according to European Clinical Trials Database record.
28 Jul 2021 Status changed from not yet recruiting to recruiting.
26 Jul 2021 Planned End Date changed from 1 Mar 2022 to 1 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com